1002317-12-5

Basic information

• Product Name: N,N-DiMethyl-1-(6-nitro-3-pyridinyl)-4-piperidinaMine
• Synonyms: N,N-DiMethyl-1-(6-nitro-3-pyridinyl)-4-piperidinaMine;N,N-dimethyl-1-(6-nitro-3-pyridyl)piperidin-4-amine
• CAS NO: 1002317-12-5
• Molecular Formula: C12H18N4O2
• Molecular Weight: 250.29692
• Mol File: 1002317-12-5.mol
• Article Data: 16

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N,N-DiMethyl-1-(6-nitro-3-pyridinyl)-4-piperidinaMine(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-DiMethyl-1-(6-nitro-3-pyridinyl)-4-piperidinaMine(1002317-12-5)
• EPA Substance Registry System: N,N-DiMethyl-1-(6-nitro-3-pyridinyl)-4-piperidinaMine(1002317-12-5)

Safety Data

• Hazardous Substances Data: 1002317-12-5(Hazardous Substances Data)

Usage

Uses

N,N-Dimethyl-1-(6-nitro-3-pyridinyl)-4-piperidinamine is used in the synthetic preparation of pyrazolyl-pyrimidines as selective inhibitors of CDK4/CDK6.

Upstream product

• 124-40-3 dimethyl amine 
• 50533-97-6 dimethyl-piperidin-4-yl-amine 
• 39856-50-3 5-bromo2-nitropyridine 
• 41661-47-6 piperidin-4-one 

Relevant articles and documents

Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation

Cyclin D dependent kinases (CDK4 and CDK6) regulate entry into S phase of the cell cycle and are validated targets for anticancer drug discovery. Herein we detail the discovery of a novel series of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as highly potent and selective inhibitors of CDK4 and CDK6. Medicinal chemistry optimization resulted in 83, an orally bioavailable inhibitor molecule with remarkable selectivity. Repeated oral administration of 83 caused marked inhibition of tumor growth in MV4-11 acute myeloid leukemia mouse xenografts without having a negative effect on body weight and showing any sign of clinical toxicity. The data merit 83 as a clinical development candidate.

DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS

A novel class of heteroaryl compounds for use in the prevention and/or treatment of proliferative diseases and conditions including cancers. The compounds are considered to be capable of inhibiting cell proliferation by inhibiting the activity of FLT3 and its mutant forms and/or other protein kinases such as CDKs. The compounds have the general structure I:

ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS

This invention is in the area of pyrimidine-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.